British American Tobacco - Press releases

BAT outlines five-step plan towards better regulation of vapour sector

Kingsley Wheaton, BAT’s Chief Strategy & Growth Officer, called for a smarter regulatory framework for vapour products to help governments worldwide deliver on their aims for a Smokefree 2030 in remarks as the Global Tobacco & Nicotine Forum 2023 (GTNF) kicked off today

Russia business update – sale completed

Further to our announcement on 7 September 2023, we have now completed the sale of our Russian and Belarusian businesses.

Russia business update – agreement signed

BAT has now formally entered into an agreement to sell its Russian and Belarusian businesses in compliance with local and international laws.

Half-Year Report for the six months to 30 June 2023

Half-Year Report for the six months to 30 June 2023

BAT announces changes to Management Board structure and composition

Following the appointment of Tadeu Marroco as Chief Executive on 15 May 2023, BAT announces changes to its Management Board.

2023 First Half Pre-Close Trading Update

2023 H1 Pre-Close Trading Update: On track to meet full year guidance

New clinical data on Vuse illustrates beneficial public health impact of Tobacco Harm Reduction

New clinical data on Vuse illustrates beneficial public health impact of Tobacco Harm Reduction

BAT announces Tadeu Marroco as Chief Executive

The Board announces the appointment of Tadeu Marroco as Chief Executive of BAT plc to succeed Jack Bowles who is stepping down from the Board of Directors with effect from 15 May.

BAT reaches agreement with U.S. Department of Justice (DOJ) and U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC)

Agreement reached with DOJ and OFAC to resolve investigations into BAT’s historical business activities in relation to North Korea from 2007-2017 BAT ceased all business activities related to North Korea by September 2017 No impact on Full Year 2023 Group guidance; investigations previously disclosed and provisions made in 2022 Half Year Report

2023 AGM: Chair's address

2023 AGM: Chair's address

Marketing Denial Order issued for Vuse Solo Menthol 4.8%

Today, U.S. Food and Drug Administration (“FDA”) has issued a Marketing Denial Order (“MDO”) for Vuse Solo’s 4.8% Menthol product.

BAT signals step change with its first combined Annual & ESG Report

Preliminary announcement - year ended 31 December 2022

Preliminary Results 2022 - quote

BAT included in prestigious 2023 Bloomberg Gender-Equality Index

BAT included in 2023 Bloomberg Gender-Equality Index in first year participating; recognises BAT’s efforts to sustain a diverse, inclusive culture.

Driving Faster Transformation at BAT: Management Board changes and a new regional structure

Following a strategic review of its regions, business units and global functions, BAT will implement a number of senior management changes and a new regional structure to both streamline, and accelerate, the transformation of its business.

MDO for Vuse Vibe Tank Menthol 3.0% and Vuse Ciro Cartridge Menthol 1.5%

Today, U.S. Food and Drug Administration (“FDA”) has issued Marketing Denial Orders (“MDOs”) for two Vuse products—the Vuse Vibe Tank Menthol 3.0% and the Vuse Ciro Cartridge Menthol 1.5%.

BAT recognised as a Global Top Employer for a sixth consecutive year

BAT is pleased to be certified as a Global Top Employer for a sixth successive year. We are accredited as a Global Top Employer for 2023 across three regions – Africa, Asia Pacific and Europe.